Monoclonal antibody infusion reaction with bamlanivimab and etesevimab in a 5-year-old male with coronavirus disease 2019: a case report
Author Department
Pediatrics; Medicine
Document Type
Article, Peer-reviewed
Publication Date
2-2023
Abstract
Background: Bamlanivimab and etesevimab had been granted emergency use authorization in children under 12 years who are at risk of progression from mild/moderate coronavirus disease 2019 to severe disease and hospitalization.
Case report: We report on a 5-year-old white male with preexisting conditions, predisposing him to severe disease, who developed hypoxia and flushing 3 minutes into his infusion, thus meeting the criteria for anaphylaxis.
Conclusions: We believe this patient developed either an immunoglobulin E-mediated anaphylactic or a non-immunoglobulin E-mediated anaphylactoid reaction to bamlanivimab and etesevimab, which is an important possibility to consider on administration.
Keywords: Anaphylactoid; Bamlanivimab; Case report; Etesevimab; Infusion reaction; Monoclonal antibody.
Recommended Citation
Pillai RLI, Dziel C, Vogel S, Szczerba F, Chang WW, Camelo IY, Paez A. Monoclonal antibody infusion reaction with bamlanivimab and etesevimab in a 5-year-old male with coronavirus disease 2019: a case report. J Med Case Rep. 2023 Feb 24;17(1):64. doi: 10.1186/s13256-023-03779-3.
PMID
36823658